Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)

Study Purpose

The purpose of this study is to learn about the safety and effects of PLG0206 for treating periprosthetic joint infections (PJI) in conjunction with the DAIR (debridement, antibiotics and implant retention) surgical procedure for patients with periprosthetic joint infections (PJI) after total knee arthroplasty (TKA) .

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 79 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patients with well-fixed prosthesis; - Patients who have a pre- or intra-operative diagnosis of TKA-PJI.

Exclusion Criteria:

- Patients for whom a DAIR procedure is not indicated; - Patients with loose prosthesis and/or surgical treatment requiring removal of well-fixed, non-modular implants at screening; - Patients with previous history or presence of osteomyelitis in the index limb; - Patients who have uncontrolled diabetes mellitus; - Patients with body mass index >50 kg/m2 at screening; - Patients who are immunosuppressed; - Patients who require therapeutic anticoagulation and/or antiplatelet therapy

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05137314
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Peptilogics
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry, U.S. Fed, Other
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Joint Infection
Additional Details

Peptilogics, Inc. is developing PLG0206 for the treatment of PJIs. PLG0206 is an engineered antibacterial peptide (EAP) based on naturally-occurring antimicrobial peptides (AMPs). Recent work on PLG0206 has documented that PLG0206 is a highly effective anti-biofilm agent, in addition to its established activity against planktonic staphylococcus, both in vitro and in a murine animal model of PJI. PLG0206 will be investigated in this study for treatment of PJI in conjunction with the DAIR procedure followed by the 6-week course of antimicrobial therapy that is standard-of-care (SOC) in this indication. Patients will be followed for approximately 1 year post treatment.

Arms & Interventions

Arms

Experimental: 3 mg/mL PLG0206

administered intraoperatively by local irrigation

Experimental: 10 mg/mL PLG0206

administered intraoperatively by local irrigation

Interventions

Drug: - PLG0206

PLG0206 is an engineered antibacterial peptide (EAP)

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Stanford Hospital, Palo Alto, California

Status

Recruiting

Address

Stanford Hospital

Palo Alto, California, 94305

Gulfcoast Research, Sarasota, Florida

Status

Recruiting

Address

Gulfcoast Research

Sarasota, Florida, 34232

LifeBridge, Baltimore, Maryland

Status

Recruiting

Address

LifeBridge

Baltimore, Maryland, 21215

Brigham & Women's Hospital, Boston, Massachusetts

Status

Recruiting

Address

Brigham & Women's Hospital

Boston, Massachusetts, 02115

NYU Langone Orthopedic Hospital, New York, New York

Status

Recruiting

Address

NYU Langone Orthopedic Hospital

New York, New York, 10003

Cleveland Clinic, Cleveland, Ohio

Status

Recruiting

Address

Cleveland Clinic

Cleveland, Ohio, 44106

Ohio State University, Columbus, Ohio

Status

Recruiting

Address

Ohio State University

Columbus, Ohio, 43203

Rothman, Philadelphia, Pennsylvania

Status

Recruiting

Address

Rothman

Philadelphia, Pennsylvania, 19107

Memorial Hermann Hospital, Houston, Texas

Status

Recruiting

Address

Memorial Hermann Hospital

Houston, Texas, 77030

Michael E. DeBakey VA Medical Center, Houston, Texas

Status

Recruiting

Address

Michael E. DeBakey VA Medical Center

Houston, Texas, 77030

University of Utah Orthopaedic Center, Salt Lake City, Utah

Status

Recruiting

Address

University of Utah Orthopaedic Center

Salt Lake City, Utah, 44106

WVU, Morgantown, West Virginia

Status

Recruiting

Address

WVU

Morgantown, West Virginia, 26501